Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Review
Grant support
21019
Cancer Research UK - United Kingdom
PubMed
30385870
DOI
10.1038/s41409-018-0373-4
PII: 10.1038/s41409-018-0373-4
Knihovny.cz E-resources
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy MeSH
- Remission Induction MeSH
- Humans MeSH
- Transplantation Conditioning methods MeSH
- Prospective Studies MeSH
- Hematopoietic Stem Cell Transplantation methods MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Geographicals
- Europe MeSH
Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the stratification systems vary among study groups. Inadequate response at the level of minimal residual disease is the most commonly accepted factor indicating the need for alloHSCT. In this consensus paper on behalf of the European Working Group for Adult Acute Lymphoblastic Leukemia and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize available evidence and reflect current clinical practice in major European study groups regarding both indications for HSCT and particular aspects of the procedure including the choice of donor, source of stem cells and conditioning. Finally, we propose recommendations for daily clinical practice as well as for planning of prospective trials.
Chaim Sheba Medical Center Tel Hashomer Israel
CHU Sart Tilman University of Liege Liege Belgium
EBMT Acute Leukemia Working Party Office Paris France
Erasmus MC Cancer Institute University Medical Center Rotterdam The Netherlands
FGBU Hematology Research Center Russia Federation Ministry of Public Health Moscow Russia
Helsinki University Hospital Helsinki Finland
Hospital Saint Antoine Paris France
ICO Hospital Germans Trias 1 Pujol Jose Carreras Research Institute Badalona Spain
IDIBAPS Hospital Clinic Barcelona Spain
Klinikum Augsburg Ludwig Maximilians Universitaet Munich Augsburg Germany
Maria Sklodowska Curie Institute Cancer Center Gliwice Branch Gliwice Poland
North London Cancer Network Univ College London Hosp London UK
San Raffaele Scientific Institute Milan Italy
Sapienza University Rome Italy
University Hospital Brno Czechia
University Hospital Goethe University Frankfurt Germany
University Hospitals Bristol National Health Service Foundation Trust Bristol UK
References provided by Crossref.org
Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
